Litoxetine (developmental code names SL 81-0385, IXA-001) is an antidepressant which was under clinical development for the treatment of depression in the early 1990s but was never marketed.  It acts as a  potent serotonin reuptake inhibitor (K i for = 7 nM) and modest SERT 5-HT 3 receptor antagonist (K i = 315 nM).  It has  antiemetic activity, and unlike the selective serotonin reuptake inhibitors (SSRIs), appears to have a negligible incidence of nausea and vomiting. The drug is structurally related to  indalpine. Development of litoxetine for depression was apparently ceased in the late 1990s.  However, as of March 2017, development of litoxetine has been reinitiated and the drug is now in the  phase II stage for the treatment of urinary incontinence.
References [ edit ]
"Litoxetine - AdisInsight". adisinsight.springer.com . Retrieved . 2018-08-25
Fairweather DB, Patat A, Rosenzweig P, Curson VH, Dunmore C, Dubruc C, Hindmarch I (August 1995). "The psychomotor and cognitive effects of litoxetine in young and middle aged volunteers". British Journal of Clinical Pharmacology. 40 (2): 119–25. doi: 10.1111/j.1365-2125.1995.tb05767.x. PMC . 1365170 PMID 8562293.
Zoran Rankovic; Richard Hargreaves; Matilda Bingham (8 October 2012). . Royal Society of Chemistry. pp. 195–. Drug Discovery for Psychiatric Disorders ISBN . 978-1-84973-494-3
^ a b
. Birkhäuser. 6 December 2012. pp. 80–. Progress in Drug Research ISBN . 978-3-0348-8391-7
Angel I, Schoemaker H, Prouteau M, Garreau M, Langer SZ (March 1993). "Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties". European Journal of Pharmacology. 232 (2–3): 139–45. doi: 10.1016/0014-2999(93)90767-C. PMID 8385615.
^ a b
External links [ edit ]